तुलना करने के लिए मीट्रिक्स | IMNM | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधIMNMपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −12.9x | −3.1x | −0.4x | |
PEG अनुपात | −0.83 | −0.06 | 0.00 | |
क़ीमत/बुक | 6.2x | 3.4x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 60.2x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | 24.7% | 39.4% | 46.0% | |
उचित मूल्य अपसाइड | अनलॉक करें | 3.1% | 5.3% | अनलॉक करें |
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.